Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

Leukemia

Volumn 27, Issue 8, 2013, Pages 1738-1744

  Rajkumar, S V ^a   Gupta, V ^a   Fonseca, R ^b   Dispenzieri, A ^a   Gonsalves, W I ^a   Larson, D ^a   Ketterling, R P ^a   Lust, J A ^a   Kyle, R A ^a   Kumar, S K ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

biomarker; cytogenetics; prognosis; smoldering multiple myeloma

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CHROMOSOME ABERRATION; FEMALE; FIBROSARCOMA; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOSOMY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION; SMOLDERING MULTIPLE MYELOMA; TRISOMY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RISK; TRANSLOCATION, GENETIC;

EID: 84881477133     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.86     Document Type: Article

References (44)

1. Rajkumar SV. Treatment of multiple myeloma. Nature Rev Clin Oncol 2011; 8: 479-491.
2. Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 225-235.
3. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149-157.
4. Sinha S, Lacy M, Mikhael J, Hayman S, Buadi F, Detweiler-Short K et al. Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. Leukemia 2012; 26: 839-841.
5. Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P, Mohty M. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Leukemia 2012; 26: 73-85.
6. Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011; 25: 906-908.
7. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417.
8. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418-5422.
9. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. A longterm study of prognosis of monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-569. (Pubitemid 34438817)
10. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362-1369.
11. Greenberg AJ, Vachon CM, Rajkumar SV. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia 2012; 26: 609-614.
12. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582-2590. (Pubitemid 46961003)
13. Rajkumar SV, Merlini G, San Miguel JF. Redefining myeloma. Nature Rev Clin Oncol 2012; 9: 494-496.
14. Blade J, Dimopoulos M, Rosinol L, Rajkumar SV, Kyle RA. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 2010; 28: 690-697.
15. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546-1558. (Pubitemid 38235629)
16. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210-2221.
17. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clinic Proc 2009; 84: 1095-1110.
18. Kaufmann H, Ackermann J, Baldia C, Nosslinger T, Wieser R, Seidl S et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 2004; 18: 1879-1882. (Pubitemid 39530019)
19. Bianchi G, Kyle RA, Larson DR, Witzig TE, Kumar S, Dispenzieri A et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 2012; 27: 680-685.
20. Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellias N, Eleftherakis-Papaiakovou E et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 2012; advance online publication 27 November 2012; doi:10.1038/leu.2012.309.
21. Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton III LJ et al. Suppression of uninvolved immunoglobulins defined by heavy/light-chain pair suppression is a risk factor for progression of MGUS. Leukemia 2012; 27: 208-212.
22. Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2012; advance online publication 27 November 2012; doi:10.1038/leu.2012.296.
23. Avet-Loiseau H, Magrangeas F, Moreau P, Attal M, Facon T, Anderson K et al. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol 2011; 29: 1893-1897.
24. Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010; 24: 623-628.
25. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
26. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
27. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100: 1417-1424. (Pubitemid 34864300)
28. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities in multiple myeloma: an Eastern Cooperative Oncology Group Study. Cancer Res 2002; 62: 715-720. (Pubitemid 34126946)
29. Fonseca R, Aguayo P, Ahmann GJ, Jalal SM, Rajkumar SV, Kyle RA et al. Translocations at 14q32 are common in patients with the monoclonal gammopathy of undetermined significance (MGUS) and involve several partner chromosomes. Blood 1999; 94(Suppl 1): 663a (A 2943).
30. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250-4256.
31. Avet-Louseau H, Daviet A, Sauner S, Bataille R. Intergroupe Francophone du M. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 2000; 111: 1116-1117. (Pubitemid 32104926)
32. Shaughnessy Jr. J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003; 120: 44-52. (Pubitemid 36056907)
33. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 17 October 2008 2007; 111: 785-789.
34. Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M et al. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia 2010; 24: 1498-1505.
35. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-1127.
36. Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-1127.
37. Alexanian R, Barlogie B, Dixon D. Prognosis of asymptomatic multiple myeloma. Arch Intern Med 1988; 148: 1963-1965.
38. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-779. (Pubitemid 36519375)
39. Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, Kumar S et al. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia 2012; 27: 220-225.
40. Barlogie B, van Rhee F, Shaughnessy Jr JD, Epstein J, Yaccoby S, Pineda-Roman M et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 2008; 112: 3122-3125.
41. Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008; 113: 1588-1595.
42. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009; 84: 114-122.
43. Golombick T, Diamond TH, Manoharan A, Ramakrishna R. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. Am J Hematol 2012; 87: 455-460.
44. Mateos M, Lopez-Corral L, Hernandez M, Giraldo P, De la Rubia J, De Arriba F et al. Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: a phase III, randomized, multicenter trial based on lenalidomide-dex-amethasone (Len-Dex) as induction therapy followed by maintenance therapy with Len alone vs no treatment. Blood 2011; 118: 3996.